Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M. Goldman

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|April 13, 2007
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remissionJiri Pavlu, Catharina Andreasson, Charles Chuah, et al.
British Journal of Haematology|July 25, 2003
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal personsMyrtle Y Gordon, Stephen B Marley, Jane F Apperley, et al.
Blood|September 27, 2003
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantationWilliam J Jordan, Paul A Brookes, Richard M Szydlo, et al.
Blood|June 21, 2008
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemiaMohamad Mohty, Richard M Szydlo, Agnes S M Yong, et al.
Blood|November 2, 2002
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTLIlaria Bellantuono, Liquan Gao, Suzanne Parry, et al.
Transplantation|June 7, 2003
Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipientsLiquan Gao, Shao-An Xue, Robert Hasserjian, et al.
Blood|April 7, 2007
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effectsAgnes S M Yong, Katayoun Rezvani, Bipin N Savani, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
Blood|March 1, 2003
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrançois-Xavier Mahon, Francis Belloc, Valérie Lagarde, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|April 13, 2007
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remissionJiri Pavlu, Catharina Andreasson, Charles Chuah, et al.
British Journal of Haematology|July 25, 2003
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal personsMyrtle Y Gordon, Stephen B Marley, Jane F Apperley, et al.
Blood|September 27, 2003
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantationWilliam J Jordan, Paul A Brookes, Richard M Szydlo, et al.
Blood|June 21, 2008
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemiaMohamad Mohty, Richard M Szydlo, Agnes S M Yong, et al.
Blood|November 2, 2002
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTLIlaria Bellantuono, Liquan Gao, Suzanne Parry, et al.
Transplantation|June 7, 2003
Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipientsLiquan Gao, Shao-An Xue, Robert Hasserjian, et al.
Blood|April 7, 2007
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effectsAgnes S M Yong, Katayoun Rezvani, Bipin N Savani, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
Blood|May 31, 2012
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinibDavid Marin, Corinne Hedgley, Richard E Clark, et al.
Blood|March 1, 2003
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrançois-Xavier Mahon, Francis Belloc, Valérie Lagarde, et al.
Pageof 10